Table 3 Patients and tumor characteristics in dependence of the intratumoral OCT3 mRNA expression
Characteristics | OCT3 (SLC22A3) Low expression (< Median) | OCT3 (SLC22A3) High expression (≥ Median) | P-value |
|---|---|---|---|
N | 23 | 26 | |
Median follow-up in days (range) | 348 (22-1531) | 423 (29-1645) | n.s. (0.36) |
Male/female (n) | 21/2 | 22/4 | n.s. (0.67) |
Median age in years (range) | 71 (35-84) | 64 (47-93) | n.s. (0.13) |
1-3 nodules/multiple nodules (specimen) | 16/7 | 18/8 | n.s. (0.98) |
Tumor diameter < 3 cm/> 3 cm | 7/16 | 11/15 | n.s. (0.55) |
Median tumor diameter in cm (range) | 5.0 (1.5-30) | 4.4 (0.1-20) | n.s. (0.98) |
T classification: T1/T2/T3 (specimen) | 6/9/8 | 10/11/5 | n.s. (0.42) |
Grading: G1/G2/G3/Gx | 3/15/5/0 | 6/15/4/1 | n.s. (0.60) |
AFP > 100/< 100 * | 4/17 | 7/19 | n.s. (0.73) |
Angioinvasion yes/no # | 3/18 | 7/17 | n.s. (0.30) |
Child A/B/C/no cirrhosis | 11/0/1/11 | 7/4/5/10 | n.s. (0.06) |
Underlying disease (HCV/HBV/alcoholic/others/unknown) | 5/2/2/6/8 | 4/6/2/8/6 | n.s. (0.64) |
SLC22A1 mRNA expression ratio HCC/TST (range) | 0.08 (0.001-1.36) | 0.4 (0.003-2.78) | 0.008 |
Pretreatment with chemoembolization (yes/no) | 6/17 | 14/12 | n.s. (0.08) |
Liver transplantation/resection | 6/17 | 13/13 | n.s. (0.14) |